Emanuel Boeminghaus wrote that the Swiss pharmaceutical company Roche has temporarily suspended all future investment decisions in Germany. Following Boehringer Ingelheim, another company is affected. Roche Germany's CEO Daniel Steiners sharply criticized the federal government and called it a political watershed. According to Boeminghaus, Roche invested around 719 million euros in German locations in 2025 and a total of around 3.8 billion euros since 2020. The company employs 18,594 people in Germany and achieved a revenue of 8.9 billion euros in 2025. In future investments, Germany competes with the USA and China, wrote Boeminghaus. Steiners demanded better local conditions and stated that Europe must try harder again. Boeminghaus described the investment freeze as a warning signal for the industrial location and a bad start to the week for Friedrich Merz. https://t.co/AGLz75iw7Z #Roche #Deutschland #Wirtschaftskrise (translated)
